Author

Nicolas Munz

Institute of Oncology ResearchORCID 0009-0005-4073-5874Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 1 Assay:long-read sequencing· 1 Assay:proteomics· 1

Frequent Co-Authors

Alberto J. ArribasiD· 3 shared Francesco BertoniiD· 3 shared Andrea RinaldiiD· 2 shared Chiara TarantelliiD· 2 shared Filippo SprianoiD· 2 shared Luciano CascioneiD· 2 shared Sara NapoliiD· 2 shared Ada H. V. Repetto‐LlamazaresiD· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Alberto J. ArribasORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyBritish Journal of HaematologyPeer-reviewedSep 18, 2025

Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes

Sebastian Patzke, Filippo Spriano, Katrine B. Melhus…·Francesco Bertoni

This paper evaluates the effectiveness of 177Lu-lilotomab satetraxetan in lymphoma cell lines, showing it is more effective in CD37-positive B-cell lymphomas and identifies potential biomarkers and synergistic combinations.

2 citations

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 10, 2024

Enhancer lncRNA LOC730338 modulates BCR signaling and immune evasion in lymphoma by regulating RNA homeostasis.

Luciano Cascione, Francesca Guidetti, Sunandini Ramnarayanan…·Sara Napoli

This paper identifies ADARreg, an elncRNA that modulates BCR signaling and immune evasion in lymphoma by altering RNA stability, localization, and editing, providing a potential therapeutic target.

1 citation

humanlong-read sequencing

𝕏 PostBluesky

Cancer BiologyBlood AdvancesPeer-reviewedOct 7, 2024

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

Alberto J. Arribas, Sara Napoli, Eugenio Gaudio…·Francesco Bertoni

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

12 citations

humanproteomics

𝕏 PostBluesky